We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Electronic Warning System for Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02455102
Recruitment Status : Completed
First Posted : May 27, 2015
Last Update Posted : December 22, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim of this randomized controlled study is to evaluate whether a newly designed electronic warning system will increase the initiation rate of adequate stroke preventive measures in patients with atrial fibrillation.

Condition or disease Intervention/treatment
Atrial Fibrillation Other: Electronic warning alert

Detailed Description:
A large proportion of patients with atrial fibrillation do not receive stroke prevention therapy in line with the guidelines, in spite of the presence of an increased risk of stroke. It will be investigated whether an electronic alert to physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will increase the rate of adequate stroke preventive measures as compared to a control group of patients without an electronic alert. The electronic alerts will be sent if patients with atrial fibrillation but without adequate stroke preventive measures receive in-patient treatment at the University Hospital Bern. The electronic alert system includes a feature that helps the physicians in charge to evaluate the CHA2DS2VASC Score. At the end of the hospital stay medical discharge letters will be reviewed for initiation of adequate stroke preventive measures.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1707 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Electronic Warning System to Improve Stroke Prevention in Atrial Fibrillation - A Quality Improvement Initiative at the University Hospital Bern
Study Start Date : September 2014
Primary Completion Date : October 2015
Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Electronic alert
Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
Other: Electronic warning alert
A newly-installed warning system for stroke prevention in atrial fibrillation.
No Intervention: No electronic alert
Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.


Outcome Measures

Primary Outcome Measures :
  1. Rate of initiation of adequate measures to prevent stroke (oral anticoagulant prescription) by physician in charge [ Time Frame: End of hospital stay (expected average duration of 1 week) ]
    Reviewed from discharge letter


Secondary Outcome Measures :
  1. Use of the CHA2DS2VASc score calculation tool by the physician in charge [ Time Frame: During hospital stay (expected average duration of 1 week) ]
  2. Rate of correct evaluation of the CHA2DS2VASC Score through the calculation tool by physician in charge [ Time Frame: End of hospital stay (expected average duration of 1 week) ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All in-patients with atrial fibrillation

Exclusion Criteria:

  • Ongoing anticoagulant therapy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02455102


Locations
Switzerland
Swiss Cardiovascular Center, Inselspital, University of Bern
Bern, Switzerland, 3012
Sponsors and Collaborators
University Hospital Inselspital, Berne
Investigators
Principal Investigator: Nils Kucher, Prof. M.D. Department of Angiology, Swiss Cardiovascular Center, University of Berne
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT02455102     History of Changes
Other Study ID Numbers: 022/14
First Posted: May 27, 2015    Key Record Dates
Last Update Posted: December 22, 2015
Last Verified: December 2015

Keywords provided by University Hospital Inselspital, Berne:
Prevention
Anticoagulation
Electronic warning system

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes